Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 110 articles:
HTML format
Text format



Single Articles


    October 2017
  1. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Text format     Abstract available


  2. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Text format     Abstract available


    September 2017
  3. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Text format     Abstract available


  4. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Text format     Abstract available


  5. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Text format     Abstract available


  6. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Text format     Abstract available


    August 2017
  7. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Text format     Abstract available


  8. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Text format     Abstract available


  9. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Text format     Abstract available


  10. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Text format     Abstract available


  11. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Text format     Abstract available


    July 2017
  12. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Text format     Abstract available


  13. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Text format     Abstract available


  14. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Text format     Abstract available


    June 2017
  15. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Text format     Abstract available


  16. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Text format     Abstract available


    May 2017
  17. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Text format     Abstract available


  18. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Text format     Abstract available


  19. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Text format     Abstract available


  20. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Text format     Abstract available


  21. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Text format     Abstract available


    April 2017
  22. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Text format     Abstract available


  23. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Text format     Abstract available


    March 2017
  24. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Text format     Abstract available


  25. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Text format     Abstract available


  26. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Text format     Abstract available


  27. JONES M, Cunningham ME, Wing P, DeSilva S, et al
    SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.
    J Med Virol. 2017 Mar 17. doi: 10.1002/jmv.24809.
    PubMed     Text format     Abstract available


    February 2017
  28. FLORES GL, Cruz HM, Marques VA, Villela-Nogueira CA, et al
    Performance of anti-HCV testing in dried blood spots and saliva according to HIV status.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24777.
    PubMed     Text format     Abstract available


  29. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24776.
    PubMed     Text format     Abstract available


    January 2017
  30. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24767.
    PubMed     Text format     Abstract available


  31. GRANDAL M, Pernas B, Marino A, Alvarez H, et al
    Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24766.
    PubMed     Text format     Abstract available


    December 2016
  32. MURAKAWA M, Asahina Y, Kawai-Kitahata F, Nakagawa M, et al
    Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    J Med Virol. 2016 Dec 30. doi: 10.1002/jmv.24763.
    PubMed     Text format     Abstract available


  33. WANG L, Chen W, WenXi, Feng J, et al
    The utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
    J Med Virol. 2016 Dec 13. doi: 10.1002/jmv.24754.
    PubMed     Text format     Abstract available


  34. ZHAO N, Liu J, Sun D
    Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay.
    J Med Virol. 2016 Dec 9. doi: 10.1002/jmv.24747.
    PubMed     Text format     Abstract available


  35. NGOC NB, Okuno Y, Ajiro M, Iida K, et al
    Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24739.
    PubMed     Text format     Abstract available


    November 2016
  36. ELFIKY AA, Mahdy SM, Elshemey WM
    Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.
    J Med Virol. 2016 Nov 19. doi: 10.1002/jmv.24736.
    PubMed     Text format     Abstract available


  37. BODEAU S, Lemouel JP, Diouf M, Duverlie G, et al
    Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24726.
    PubMed     Text format     Abstract available


  38. SALEMI JL, Spooner KK, Mejia de Grubb MC, Aggarwal A, et al
    National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24725.
    PubMed     Text format     Abstract available


    October 2016
  39. HUMAYED SM, El-Mekki AA, Mahfouz AA
    Hepatitis C virus infection in south-western Saudi Arabia: Are we still in the plateau phase?
    J Med Virol. 2016 Oct 13. doi: 10.1002/jmv.24712.
    PubMed     Text format     Abstract available


    September 2016
  40. TSUKUDA Y, Suda G, Tsunematsu S, Ito J, et al
    Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection.
    J Med Virol. 2016 Sep 24. doi: 10.1002/jmv.24692.
    PubMed     Text format     Abstract available


  41. ROUABHIA S, Chaabna K
    Hepatitis C infection in eastern Algeria: Between statistics and reality.
    J Med Virol. 2016 Sep 14. doi: 10.1002/jmv.24686.
    PubMed     Text format     Abstract available


  42. ELFIKY AA
    Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24678.
    PubMed     Text format     Abstract available


  43. NAKAMURA Y, Imamura M, Kawakami Y, Teraoka Y, et al
    Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24679.
    PubMed     Text format     Abstract available


  44. EL-EKIABY NM, Mekky RY, Riad SE, Elhelw DS, et al
    miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models.
    J Med Virol. 2016 Sep 3. doi: 10.1002/jmv.24677.
    PubMed     Text format     Abstract available


    August 2016
  45. WU S, Yan P, Yang T, Wang Z, et al
    Epidemiological profile and risk factors of HIV and HBV/HCV co-infection in Fujian Province, southeastern China.
    J Med Virol. 2016 Aug 23. doi: 10.1002/jmv.24666.
    PubMed     Text format     Abstract available


  46. MARCIANO S, Haddad L, Plazzotta F, Mauro E, et al
    Implementation of the ECHO(R) telementoring model for the treatment of patients with hepatitis C.
    J Med Virol. 2016 Aug 23. doi: 10.1002/jmv.24668.
    PubMed     Text format     Abstract available


  47. KOBAYASHI M, Suzuki F, Fujiyama S, Kawamura Y, et al
    Sustained virologic response by direct anti-viral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    J Med Virol. 2016 Aug 17. doi: 10.1002/jmv.24663.
    PubMed     Text format     Abstract available


  48. HAYES CN, Chayama K
    Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses.
    J Med Virol. 2016 Aug 10. doi: 10.1002/jmv.24659.
    PubMed     Text format     Abstract available


    July 2016
  49. DE PASCHALE M, Manco MT, Belvisi L, Cagnin D, et al
    Evaluation of LIAISON(R) XL system for HBsAg, and anti-HCV and anti-HIV/Ag p24.
    J Med Virol. 2016 Jul 28. doi: 10.1002/jmv.24648.
    PubMed     Text format     Abstract available


  50. REBBANI K, Ababou M, Nadifi S, Kandil M, et al
    Myxovirus resistance 1 gene polymorphisms and outcomes of viral hepatitis B and C infections in Moroccan patients.
    J Med Virol. 2016 Jul 26. doi: 10.1002/jmv.24642.
    PubMed     Text format     Abstract available


  51. HOULDSWORTH A
    Exploring the possibility of arthropod transmission of HCV.
    J Med Virol. 2016 Jul 22. doi: 10.1002/jmv.24638.
    PubMed     Text format     Abstract available


  52. MORISCO F, Loperto I, Stroffolini T, Lombardo FL, et al
    Prevalence and risk factors of HCV infection in a metropolitan area in Southern Italy: Tail of a cohort infected in past decades.
    J Med Virol. 2016 Jul 19. doi: 10.1002/jmv.24635.
    PubMed     Text format     Abstract available


    June 2016
  53. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24617.
    PubMed     Text format     Abstract available


  54. IKEDA H, Watanabe T, Okuse C, Matsumoto N, et al
    Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    J Med Virol. 2016 Jun 22. doi: 10.1002/jmv.24608.
    PubMed     Text format     Abstract available


  55. LIN JW, Chang ML, Hsu CW, Chen YC, et al
    Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy.
    J Med Virol. 2016 Jun 8. doi: 10.1002/jmv.24595.
    PubMed     Text format     Abstract available


  56. AKUTA N, Sezaki H, Suzuki F, Kawamura Y, et al
    Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
    J Med Virol. 2016 Jun 3. doi: 10.1002/jmv.24592.
    PubMed     Text format     Abstract available


  57. CHUNG A, Jin B, Han KH, Ahn SH, et al
    Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes.
    J Med Virol. 2016 Jun 2. doi: 10.1002/jmv.24591.
    PubMed     Text format     Abstract available


  58. DIRCHWOLF M, Marciano S, Mauro E, Ruf A, et al
    Clinical epidemiology of acute hepatitis C in South America.
    J Med Virol. 2016 Jun 2. doi: 10.1002/jmv.24588.
    PubMed     Text format     Abstract available


    May 2016
  59. HELAL GK, Gad MA, Abd-Ellah MF, Eid MS, et al
    Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
    J Med Virol. 2016 May 16. doi: 10.1002/jmv.24575.
    PubMed     Text format     Abstract available


  60. ALBERTI A, Lacoin L, Morais E, Lefevre C, et al
    A literature review of the distribution of hepatitis C virus genotypes across Europe.
    J Med Virol. 2016 May 12. doi: 10.1002/jmv.24573.
    PubMed     Text format     Abstract available


  61. BANG BR, Elmasry S, Saito T
    Organ system view of the hepatic innate immunity in HCV infection.
    J Med Virol. 2016 May 6. doi: 10.1002/jmv.24569.
    PubMed     Text format     Abstract available


    April 2016
  62. WANG LS, D'Souza LS, Jacobson IM
    Hepatitis C- A clinical review.
    J Med Virol. 2016 Apr 20. doi: 10.1002/jmv.24554.
    PubMed     Text format     Abstract available


    March 2016
  63. SILVA MC, Silva CA, Machado GU, Atta A, et al
    HCV/HTLV coinfection: Does HTLV-1 interfere in the natural history of HCV-related diseases?
    J Med Virol. 2016 Mar 30. doi: 10.1002/jmv.24538.
    PubMed     Text format     Abstract available


  64. PEDERSEN J, Lundbo LF, Krarup H, Bukh J, et al
    Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
    J Med Virol. 2016 Mar 29. doi: 10.1002/jmv.24537.
    PubMed     Text format     Abstract available


  65. CHAIWONG S, Sistayanarain A
    Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from thai blood donors.
    J Med Virol. 2016 Mar 27. doi: 10.1002/jmv.24536.
    PubMed     Text format     Abstract available


  66. TAHATA Y, Hiramatsu N, Oze T, Urabe A, et al
    The impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    J Med Virol. 2016 Mar 18. doi: 10.1002/jmv.24528.
    PubMed     Text format     Abstract available


  67. COPPOLA N, Minichini C, Starace M, Sagnelli C, et al
    Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.
    J Med Virol. 2016 Mar 18. doi: 10.1002/jmv.24527.
    PubMed     Text format     Abstract available


  68. EL-GHITANY EM, Farghaly AG, Abdel Wahab MM, Farag S, et al
    Towards a simple risk assessment screening tool for HCV infection in Egypt.
    J Med Virol. 2016 Mar 11. doi: 10.1002/jmv.24520.
    PubMed     Text format     Abstract available


  69. AKHTAR A, Khan AH, Sulaiman SA, Soo CT, et al
    HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia.
    J Med Virol. 2016;88:455-60.
    PubMed     Text format     Abstract available


    February 2016
  70. LIU Y, Chen L, Zou Z, Zhu B, et al
    Hepatitis C virus infection induces elevation of CXCL10 in human brain microvascular endothelial cells.
    J Med Virol. 2016 Feb 19. doi: 10.1002/jmv.24504.
    PubMed     Text format     Abstract available


  71. AL-MUGHALES JA
    Co-infection assessment in HBV, HCV and HIV patients in western Saudi Arabia.
    J Med Virol. 2016 Feb 19. doi: 10.1002/jmv.24503.
    PubMed     Text format     Abstract available


  72. AROUCHA DC, Carmo RF, Vasconcelos LR, Lima RE, et al
    TNF-alpha and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals.
    J Med Virol. 2016 Feb 17. doi: 10.1002/jmv.24501.
    PubMed     Text format     Abstract available


  73. LI M, Wang W, Jin R, Zhang T, et al
    Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.
    J Med Virol. 2016 Feb 17. doi: 10.1002/jmv.24498.
    PubMed     Text format     Abstract available


  74. BENSALEM A, Selmani K, Narjes H, Bencherifa N, et al
    Eastern region represents a worrying cluster of active hepatitis C in Algeria in 2012.
    J Med Virol. 2016 Feb 9. doi: 10.1002/jmv.24491.
    PubMed     Text format     Abstract available


    January 2016
  75. D'ETTORRE G, Ceccarelli G, Serafino S, Giustini N, et al
    Dominant enrichment of phenotypically activated CD38 HLA-DR CD8 T cells, rather than CD38 HLA-DR CD4 T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    J Med Virol. 2016 Jan 14. doi: 10.1002/jmv.24475.
    PubMed     Text format     Abstract available


  76. BOKHARAEI-SALIM F, Keyvani H, Esghaei M, Zare-Karizi S, et al
    Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection.
    J Med Virol. 2016 Jan 14. doi: 10.1002/jmv.24474.
    PubMed     Text format     Abstract available


  77. TRIMBITAS RD, Fayssel N, Serghini FZ, Wakrim L, et al
    Molecular characterization of hepatitis C virus core region in Moroccan intravenous drug users.
    J Med Virol. 2016 Jan 11. doi: 10.1002/jmv.24470.
    PubMed     Text format     Abstract available


  78. ESMAT G, El Raziky M, Nabeel MM, Maher R, et al
    Seroprevalence of HCV among Cairo University students in Egypt.
    J Med Virol. 2016 Jan 11. doi: 10.1002/jmv.24469.
    PubMed     Text format     Abstract available


  79. ABDELRAHIM SS, Khiry RM, Esmail MA, Ragab M, et al
    Occult hepatitis C virus infection among Egyptian hemodialysis patients.
    J Med Virol. 2016 Jan 7. doi: 10.1002/jmv.24467.
    PubMed     Text format     Abstract available


  80. ARAIN A, Bourgeois S, de Galocsy C, Henrion J, et al
    Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
    J Med Virol. 2016;88:94-9.
    PubMed     Text format     Abstract available


    December 2015
  81. NDIAYE O, Gozlan J, Diop-Ndiaye H, Sall AS, et al
    Usefulness of Dried Blood Spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal.
    J Med Virol. 2015 Dec 24. doi: 10.1002/jmv.24460.
    PubMed     Text format     Abstract available


    November 2015
  82. DE ARAUJO MARIZ C, Lopes EP, Ximenes RA, Lacerda HR, et al
    Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis.
    J Med Virol. 2015 Nov 18. doi: 10.1002/jmv.24432.
    PubMed     Text format     Abstract available


  83. WEIL C, Nwankwo C, Friedman M, Kenet G, et al
    Epidemiology of Hepatitis C Virus Infection in a Large Israeli Health Maintenance Organization.
    J Med Virol. 2015 Nov 5. doi: 10.1002/jmv.24426.
    PubMed     Text format     Abstract available


    October 2015
  84. ZHU JW, Liu FL, Mu D, Deng DY, et al
    Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
    J Med Virol. 2015 Oct 31. doi: 10.1002/jmv.24419.
    PubMed     Text format     Abstract available


  85. FU J, Guo D, Gao D, Huang W, et al
    Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses.
    J Med Virol. 2015 Oct 28. doi: 10.1002/jmv.24417.
    PubMed     Text format     Abstract available


  86. ZABALETA A, Riezu-Boj JI, Larrea E, Villanueva L, et al
    Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.
    J Med Virol. 2015 Oct 8. doi: 10.1002/jmv.24399.
    PubMed     Text format     Abstract available


  87. MOUSSA S, Brah S, Parola P, Gerolami R, et al
    Epidemiological, clinical, virological features of hepatitis B newly diagnosed in 2011 in Marseille University hospitals, southeastern France.
    J Med Virol. 2015 Oct 6. doi: 10.1002/jmv.24398.
    PubMed     Text format     Abstract available


    August 2015
  88. AKUTA N, Sezaki H, Suzuki F, Kawamura Y, et al
    Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
    J Med Virol. 2015 Aug 20. doi: 10.1002/jmv.24360.
    PubMed     Text format     Abstract available


  89. QI Y, Chen Q, Hao F, Wan Z, et al
    Subtype distribution of hepatitis C virus in Jiangsu, China.
    J Med Virol. 2015 Aug 19. doi: 10.1002/jmv.24356.
    PubMed     Text format     Abstract available


  90. ESMAIL MA, Hassuna NA, Amr KS, Ghazawy ER, et al
    Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.
    J Med Virol. 2015 Aug 17. doi: 10.1002/jmv.24354.
    PubMed     Text format     Abstract available


  91. FABRIZI F, Dixit V, Martin P, Messa P, et al
    Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis.
    J Med Virol. 2015 Aug 13. doi: 10.1002/jmv.24353.
    PubMed     Text format     Abstract available


  92. FABRIZI F, Messa P, Martin P
    Reply to the letter by Pan Yanna et al. 'treatment of hepatitis C after kidney transplant: A pooled analysis of observational studies'.
    J Med Virol. 2015;87:1256-7.
    PubMed     Text format    


  93. PAN YN, Luo YJ, He S
    Comment on Fabrizi et al.: Treatment of hepatitis C after kidney transplant: A pooled analysis of observational studies.
    J Med Virol. 2015;87:1255.
    PubMed     Text format    


    July 2015
  94. LEE SS, Jeong SH, Jang ES, Kim YS, et al
    Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.
    J Med Virol. 2015 Jul 25. doi: 10.1002/jmv.24335.
    PubMed     Text format     Abstract available


  95. MATSUURA K, Tanaka Y
    Host genetic variants influencing the clinical course of hepatitis C virus infection.
    J Med Virol. 2015 Jul 25. doi: 10.1002/jmv.24334.
    PubMed     Text format     Abstract available


  96. BARTOLOME J, Castillo I, Quiroga JA, Carreno V, et al
    Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection.
    J Med Virol. 2015 Jul 3. doi: 10.1002/jmv.24322.
    PubMed     Text format     Abstract available


  97. HANAFY AS, Farag AA, Hassanin HM, Hassaneen AM, et al
    Recombinant HBV vaccine enhances the rate of sustained virological response when early initiated after anti-HCV combination therapy.
    J Med Virol. 2015 Jul 3. doi: 10.1002/jmv.24317.
    PubMed     Text format     Abstract available


  98. WANG J, Liu S, Cao Y, Yang L, et al
    Prevalence of Kaposi's sarcoma associated herpesvirus among men attending sexually transmitted infections clinics in Anhui, China.
    J Med Virol. 2015 Jul 3. doi: 10.1002/jmv.24321.
    PubMed     Text format     Abstract available


    June 2015
  99. CHEN S, Li S, Chen L
    Interferon-inducible protein 6-16 (IFI-6-16, ISG16) promotes hepatitis C virus replication in vitro.
    J Med Virol. 2015 Jun 23. doi: 10.1002/jmv.24302.
    PubMed     Text format     Abstract available


  100. AZIZ H, Raza A, Irfan J
    Optimum predictors of therapeutic outcome in HCV patients in Pakistan.
    J Med Virol. 2015 Jun 23. doi: 10.1002/jmv.24305.
    PubMed     Text format     Abstract available


  101. LUCCHESE A
    A potential peptide pathway from viruses to oral lichen planus.
    J Med Virol. 2015;87:1060-5.
    PubMed     Text format     Abstract available


    May 2015
  102. SUN W, Li Q, Zhu D, Feng J, et al
    Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag.
    J Med Virol. 2015 May 25. doi: 10.1002/jmv.24277.
    PubMed     Text format     Abstract available


  103. IWASAKI Y, Okamoto RI, Ishii Y, Araki Y, et al
    Randomized trial of low-dose peginterferon alpha-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.
    J Med Virol. 2015 May 22. doi: 10.1002/jmv.24276.
    PubMed     Text format     Abstract available


  104. GARCIA COMAS L, Ordobas Gavin M, Sanz Moreno JC, Ramos Blazquez B, et al
    Prevalence of hepatitis C antibodies in the population aged 16-80 years in the Community of Madrid 2008-2009.
    J Med Virol. 2015 May 18. doi: 10.1002/jmv.24219.
    PubMed     Text format     Abstract available


  105. GROTTO RM, Picelli N, de Souza LD, Silva GF, et al
    Human Platelet Polymorphism can be a genetic marker associated with HIV/HCV coinfection.
    J Med Virol. 2015 May 14. doi: 10.1002/jmv.24233.
    PubMed     Text format     Abstract available


  106. OLMEDO DB, Cader SA, Porto LC
    IFN-lambda gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.
    J Med Virol. 2015 May 12. doi: 10.1002/jmv.24227.
    PubMed     Text format     Abstract available


  107. SAMIMI-RAD K, Sadeghi F, Amirzargar A, Eshraghian MR, et al
    Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran.
    J Med Virol. 2015 May 12. doi: 10.1002/jmv.24211.
    PubMed     Text format     Abstract available


  108. ARAI T, Atsukawa M, Tsubota A, Kondo C, et al
    Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
    J Med Virol. 2015 May 11. doi: 10.1002/jmv.24244.
    PubMed     Text format     Abstract available


  109. HAJJI H, Aherfi S, Motte A, Ravaux I, et al
    Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille University Hospitals, Southeastern France.
    J Med Virol. 2015 May 8. doi: 10.1002/jmv.24261.
    PubMed     Text format     Abstract available


    March 2015
  110. MAKSYUTOV RA, Gavrilova EV, Maksyutov AZ, Kanev AN, et al
    Genotyping of hepatitis B and C virus Russian isolates for reference serum panel construction.
    J Med Virol. 2015 Mar 10. doi: 10.1002/jmv.24170.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: